|
Apr 10
|
An Intrinsic Calculation For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Suggests It's 47% Undervalued
|
|
Apr 9
|
EXEL or REGN: Which Is the Better Value Stock Right Now?
|
|
Apr 9
|
11 Best Biotech ETFs To Buy
|
|
Apr 7
|
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
|
|
Apr 6
|
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen impressive returns of 146% over the past five years
|
|
Apr 5
|
Should You Sell This Stock Following a Regulatory Roadblock?
|
|
Apr 4
|
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
|
|
Apr 4
|
LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
|
|
Apr 1
|
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
|
|
Mar 28
|
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
|
|
Mar 28
|
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
|
|
Mar 28
|
Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup
|
|
Mar 26
|
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
|
|
Mar 26
|
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
|
|
Mar 26
|
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
|
|
Mar 25
|
FDA rejects Regeneron lymphoma drug, setting back company’s oncology push
|
|
Mar 25
|
UPDATE 3-Regeneron's blood cancer therapy faces setback as FDA raises trial concerns
|
|
Mar 25
|
Regeneron Provides Update on Biologics License Application for Odronextamab
|
|
Mar 22
|
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
|
|
Mar 18
|
US appeals court revives Regeneron's antitrust lawsuit against Novartis
|